BioDelivery Sciences International, Inc. (NASDAQ:BDSI) has earned an average rating of “Buy” from the eight brokerages that are presently covering the firm, Marketbeat.com reports. Three analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $4.80.

A number of brokerages have weighed in on BDSI. HC Wainwright reiterated a “buy” rating and issued a $5.00 price target on shares of BioDelivery Sciences International in a report on Friday, November 2nd. Janney Montgomery Scott lifted their price target on shares of BioDelivery Sciences International to $5.00 and gave the company a “buy” rating in a report on Friday, November 2nd. Cantor Fitzgerald set a $5.00 price target on shares of BioDelivery Sciences International and gave the company a “buy” rating in a report on Friday, October 26th. Zacks Investment Research lowered shares of BioDelivery Sciences International from a “buy” rating to a “hold” rating in a report on Monday, October 15th. Finally, BidaskClub lowered shares of BioDelivery Sciences International from a “buy” rating to a “hold” rating in a report on Tuesday, November 13th.

In other news, Director Francis E. Odonnell, Jr. sold 8,000 shares of the firm’s stock in a transaction on Thursday, November 1st. The shares were sold at an average price of $3.84, for a total value of $30,720.00. Following the transaction, the director now owns 522,187 shares of the company’s stock, valued at approximately $2,005,198.08. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Francis E. Odonnell, Jr. sold 151,039 shares of the firm’s stock in a transaction on Thursday, September 13th. The shares were sold at an average price of $2.84, for a total transaction of $428,950.76. Following the completion of the transaction, the director now directly owns 520,482 shares in the company, valued at approximately $1,478,168.88. The disclosure for this sale can be found here. In the last quarter, insiders sold 167,039 shares of company stock worth $481,671. 13.26% of the stock is owned by company insiders.

Hedge funds have recently modified their holdings of the company. Bank of Montreal Can purchased a new position in shares of BioDelivery Sciences International in the 2nd quarter valued at $138,000. PNC Financial Services Group Inc. purchased a new position in shares of BioDelivery Sciences International in the 2nd quarter valued at $148,000. Worth Venture Partners LLC purchased a new position in shares of BioDelivery Sciences International in the 3rd quarter valued at $167,000. Dimensional Fund Advisors LP purchased a new position in shares of BioDelivery Sciences International in the 3rd quarter valued at $255,000. Finally, Wells Fargo & Company MN raised its stake in shares of BioDelivery Sciences International by 121.7% in the 3rd quarter. Wells Fargo & Company MN now owns 118,060 shares of the specialty pharmaceutical company’s stock valued at $331,000 after acquiring an additional 64,803 shares during the period. 44.01% of the stock is currently owned by institutional investors and hedge funds.

Shares of BDSI stock opened at $3.80 on Monday. BioDelivery Sciences International has a 1 year low of $1.70 and a 1 year high of $4.14. The firm has a market capitalization of $268.69 million, a P/E ratio of -9.74 and a beta of 0.09. The company has a quick ratio of 2.77, a current ratio of 3.00 and a debt-to-equity ratio of 1.42.

BioDelivery Sciences International (NASDAQ:BDSI) last announced its earnings results on Thursday, November 8th. The specialty pharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.14) by $0.04. The firm had revenue of $14.16 million for the quarter, compared to analyst estimates of $14.21 million. BioDelivery Sciences International had a negative net margin of 85.93% and a negative return on equity of 141.35%. Analysts forecast that BioDelivery Sciences International will post -0.59 EPS for the current fiscal year.

BioDelivery Sciences International Company Profile

BioDelivery Sciences International, Inc, a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. The company provides its products based on its patented BioErodible MucoAdhesive drug delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies.

Featured Article: What are the benefits of a balanced fund?

Analyst Recommendations for BioDelivery Sciences International (NASDAQ:BDSI)

Receive News & Ratings for BioDelivery Sciences International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International and related companies with MarketBeat.com's FREE daily email newsletter.